Seres Therapeutics Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | +47.5% | -11.9% | +22.1% | -3.7% | +336.3% | -95.1% | +1,672.2% | -100.0% | – | |
| – | -93.2% | +11,162.2% | +9.1% | +7.3% | -16.5% | +13.0% | +56.7% | -99.3% | +1,826.4% | -81.7% | +17.0% | |
| – | – | – | – | – | +22.1% | -266.2% | – | -95.8% | -415.8% | – | – | |
| – | +255.4% | +115.2% | +9.1% | +7.3% | -16.5% | +13.0% | +56.7% | -22.7% | +7.2% | -45.1% | -24.1% | |
| – | +284.1% | +94.6% | +4.4% | -4.2% | -24.1% | +24.4% | +125.1% | +1.4% | +10.3% | -31.4% | -26.4% | |
| – | +263.7% | +108.9% | +7.8% | +4.1% | -17.2% | -71.1% | +580.5% | -14.1% | -2.3% | -33.0% | -23.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +74.6% | +64.1% | -26.3% | -57.2% | +482.5% | -0.5% | +106.9% | +118.9% | -100.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -149.4% | – | -171.3% | – | -549.7% | – | – | – | +307.6% | -99.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.